Imatinib

Generic Name: Imatinib

Brand Names: Gleevec, Glivec, Imatinib Teva, Imatinib Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₁N_₇O

CAS Number: 152459-95-5

Unique Ingredient Identifier: BKJ8M8G5HI

Background: Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient.

Indication: Imatinib is indicated for the treatment of adult and pediatric chronic myeloid leukemia with Philadelphia chromosome mutation (Ph+) in blast crisis, accelerated phase, or chronic phase after IFN-alpha therapy failure.Additionally, imatinib is also indicated to treat adult and pediatric Ph+ acute lymphoblastic leukemia, adult myelodysplastic/myeloproliferative diseases, adult aggressive systemic mastocytosis, adult hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), adult dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).

Associated Conditions: Accelerated Phase Chronic Myelogenous Leukemia (CML), Aggressive Systemic Mastocytosis, Chordomas, Chronic Eosinophilic Leukemia, FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia, FIP1L1-PDGFRα fusion kinase status unknown Hypereosinophilic syndrome, Gastrointestinal Stromal Tumor (GIST), Hypereosinophilic Syndrome (HES), Metastatic Gastrointestinal Stromal Tumor (GIST), Metastatic Melanoma, Myelodysplastic Syndrome, Myeloproliferative Disorders (MPD), Refractory Acute Lymphoblastic Leukemia (ALL), Blast phase Chronic myeloid leukemia, CKit mutational status unknown Aggressive systemic mastocytosis, Metastatic Dermatofibrosarcoma protuberans, Newly diagnosed Acute Lymphoblastic Leukaemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Recurrent Dermatofibrosarcoma protuberans, Refractory, chronic phase Chronic myeloid leukemia, Unresectable Gastrointestinal stromal tumor

Associated Therapies: -

Clinical Trials

Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.

Phase 2

Conditions: Acute Lymphocytic Leukemia

First Posted Date: 2005-09-08

Last Posted Date: 2007-04-27

Lead Sponsor: Hospices Civils de Lyon

Target Recruit Count: 30

Registration Number: NCT00149136

Locations: 🇫🇷
Xavier THOMAS, Lyon, France

Efficacy and Safety of Imatinib in Chordoma

Phase 2

Completed

Conditions: Chordoma

Interventions: Drug: imatinib

First Posted Date: 2005-09-08

Last Posted Date: 2017-02-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 55

Registration Number: NCT00150072

Locations: 🇨🇭
Novartis Investigative Site, Lausanne, Switzerland

Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)

Phase 2

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: imatinib
Drug: cyclophosphamide
Drug: daunorubicin
Drug: vincristine
Drug: prednisolone
Drug: methotrexate
Drug: cytarabine
Drug: dexamethasone

First Posted Date: 2005-08-15

Last Posted Date: 2008-11-14

Lead Sponsor: Japan Adult Leukemia Study Group

Target Recruit Count: 100

Registration Number: NCT00130195

Locations: 🇯🇵
Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)

Phase 3

Completed

Conditions: Sarcoma

Interventions: Drug: imatinib mesylate
Drug: imatinib

First Posted Date: 2005-07-01

Last Posted Date: 2011-12-30

Lead Sponsor: Scandinavian Sarcoma Group

Target Recruit Count: 400

Registration Number: NCT00116935

Locations: 🇸🇪
Scandinavian Sarcoma Group, Southern Swedish Regional Tumour Registry, Lund University Hospital, Lund, Sweden

Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma

Phase 2

Terminated

Conditions: Thyroid Cancer

Interventions: Drug: Imatinib

First Posted Date: 2005-06-24

Last Posted Date: 2014-04-21

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 11

Registration Number: NCT00115739

Locations: 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States

Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

Phase 2

Completed

Conditions: Chronic Myeloid Leukemia
Philadelphia-Positive Myeloid Leukemia

Interventions: Drug: Dasatinib
Drug: Imatinib

First Posted Date: 2005-02-16

Last Posted Date: 2010-08-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 150

Registration Number: NCT00103844

Locations: 🇬🇧
Local Institution, Newcastle, Tyne and Wear, United Kingdom

Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Phase 1

Terminated

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Blastic Phase Chronic Myelogenous Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Chronic Phase Chronic Myelogenous Leukemia
Relapsing Chronic Myelogenous Leukemia